Glioma proteomics: Status and perspectives

Journal of Proteomics

Volumn 73, Issue 10, 2010, Pages 1823-1838

  Niclou, Simone P ^a   Fack, Fred ^a   Rajcevic, Uros ^b  

^a LUXEMBOURG INSTITUTE OF HEALTH   (Luxembourg)

^b NATIONAL INSTITUTE OF BIOLOGY   (Slovenia)

Author keywords

Astrocytoma; Biomarker; Brain tumor; Glioma; Mass spectrometry; Metabolomics; Proteome

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; AMINO ACID; BBR 3464; CISPLATIN; NITROSOUREA; PROTEOME; TEMOZOLOMIDE; TUMOR MARKER;

ANTINEOPLASTIC ACTIVITY; DECISION MAKING; GEL ELECTROPHORESIS; GLIOMA; HUMAN; LIQUID CHROMATOGRAPHY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; METABOLOMICS; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEOMICS; REVIEW; TANDEM MASS SPECTROMETRY; TREATMENT RESPONSE;

ANTIBODIES, NEOPLASM; BRAIN NEOPLASMS; CHROMATOGRAPHY, LIQUID; GLIOMA; HUMANS; NEOPLASM PROTEINS; PROTEOMICS; TANDEM MASS SPECTROMETRY; TUMOR MARKERS, BIOLOGICAL;

ANIMALIA;

EID: 77956418572     PISSN: 18743919     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jprot.2010.03.007     Document Type: Review

References (87)

1. Davis F.G., Freels S., Grutsch J., Barlas S., Brem S. Survival rates in patients with primary malignant brain tumors stratified by patient age and tumor histological type: an analysis based on Surveillance, Epidemiology, and End Results (SEER) data, 1973-1991. J Neurosurg 1998, 88:1-10.
2. Kleihues P., Sobin L.H. World Health Organization classification of tumors. Cancer 2000, 88:2887.
3. Holland E.C. Gliomagenesis: genetic alterations and mouse models. Nat Rev Genet 2001, 2:120-129.
4. Kanu O.O., Hughes B., Di C., Lin N., Fu J., Bigner D.D., Yan H., Adamson C. Glioblastoma multiforme oncogenomics and signaling pathways. Clin Med Oncol 2009, 3:39-52.
5. Reardon D.A., Wen P.Y., Desjardins A., Batchelor T.T., Vredenburgh J.J. Glioblastoma multiforme: an emerging paradigm of anti-VEGF therapy. Expert Opin Biol Ther 2008, 8:541-553.
6. Vredenburgh J.J., Desjardins A., Herndon J.E., Marcello J., Reardon D.A., Quinn J.A., Rich J.N., Sathornsumetee S., Gururangan S., Sampson J., Wagner M., Bailey L., Bigner D.D., Friedman A.H., Friedman H.S. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 2007, 25:4722-4729.
7. Aldape K., Simmons M.L., Davis R.L., Miike R., Wiencke J., Barger G., Lee M., Chen P., Wrensch M. Discrepancies in diagnoses of neuroepithelial neoplasms: the San Francisco Bay Area Adult Glioma Study. Cancer 2000, 88:2342-2349.
8. Bruner J.M., Inouye L., Fuller G.N., Langford L.A. Diagnostic discrepancies and their clinical impact in a neuropathology referral practice. Cancer 1997, 79:796-803.
9. Intraobserver reproducibility in assigning brain tumors to classes in the World Health Organization diagnostic scheme. The Childhood Brain Tumor Consortium. J Neurooncol 1989, 7:211-224.
10. Cha S. CNS tumors: monitoring therapeutic response and outcome prediction. Top Magn Reson Imaging 2006, 17:63-68.
11. Verhoeff J.J., van Tellingen O., Claes A., Stalpers L.J., van Linde M.E., Richel D.J., Leenders W.P., van Furth W.R. Concerns about anti-angiogenic treatment in patients with glioblastoma multiforme. BMC Cancer 2009, 9:444.
12. Schiess R., Wollscheid B., Aebersold R. Targeted proteomic strategy for clinical biomarker discovery. Mol Oncol 2009, 3:33-44.
13. Anderson N.L., Anderson N.G. The human plasma proteome: history, character, and diagnostic prospects. Mol Cell Proteomics 2002, 1:845-867.
14. Rajcevic U., Niclou S.P., Jimenez C.R. Proteomics strategies for target identification and biomarker discovery in cancer. Front Biosci 2009, 14:3292-3303.
15. Aebersold R., Mann M. Mass spectrometry-based proteomics. Nature 2003, 422:198-207.
16. Yates J.R., Ruse C.I., Nakorchevsky A. Proteomics by mass spectrometry: approaches, advances, and applications. Annu Rev Biomed Eng 2009, 11:49-79.
17. Hunt D.F., Yates J.R., Shabanowitz J., Winston S., Hauer C.R. Protein sequencing by tandem mass spectrometry. Proc Natl Acad Sci USA 1986, 83:6233-6237.
18. Link A.J., Eng J., Schieltz D.M., Carmack E., Mize G.J., Morris D.R., Garvik B.M., Yates J.R. Direct analysis of protein complexes using mass spectrometry. Nat Biotechnol 1999, 17:676-682.
19. Mauri P., Scigelova M. Multidimensional protein identification technology for clinical proteomic analysis. Clin Chem Lab Med 2009, 47:636-646.
20. Chen Y., Kim S.C., Zhao Y. High-throughput identification of in-gel digested proteins by rapid, isocratic HPLC/MS/MS. Anal Chem 2005, 77:8179-8184.
21. Griffin T.J., Gygi S.P., Rist B., Aebersold R., Loboda A., Jilkine A., Ens W., Standing K.G. Quantitative proteomic analysis using a MALDI quadrupole time-of-flight mass spectrometer. Anal Chem 2001, 73:978-986.
22. Old W.M., Meyer-Arendt K., Aveline-Wolf L., Pierce K.G., Mendoza A., Sevinsky J.R., Resing K.A., Ahn N.G. Comparison of label-free methods for quantifying human proteins by shotgun proteomics. Mol Cell Proteomics 2005, 4:1487-1502.
23. Zhang B., VerBerkmoes N.C., Langston M.A., Uberbacher E., Hettich R.L., Samatova N.F. Detecting differential and correlated protein expression in label-free shotgun proteomics. J Proteome Res 2006, 5:2909-2918.
24. Ong S.E., Blagoev B., Kratchmarova I., Kristensen D.B., Steen H., Pandey A., Mann M. Stable isotope labeling by amino acids in cell culture, SILAC, as a simple and accurate approach to expression proteomics. Mol Cell Proteomics 2002, 1:376-386.
25. Kruger M., Moser M., Ussar S., Thievessen I., Luber C.A., Forner F., Schmidt S., Zanivan S., Fassler R., Mann M. SILAC mouse for quantitative proteomics uncovers kindlin-3 as an essential factor for red blood cell function. Cell 2008, 134:353-364.
26. Gygi S.P., Rist B., Gerber S.A., Turecek F., Gelb M.H., Aebersold R. Quantitative analysis of complex protein mixtures using isotope-coded affinity tags. Nat Biotechnol 1999, 17:994-999.
27. Ross P.L., Huang Y.N., Marchese J.N., Williamson B., Parker K., Hattan S., Khainovski N., Pillai S., Dey S., Daniels S., Purkayastha S., Juhasz P., Martin S., Bartlet-Jones M., He F., Jacobson A., Pappin D.J. Multiplexed protein quantitation in Saccharomyces cerevisiae using amine-reactive isobaric tagging reagents. Mol Cell Proteomics 2004, 3:1154-1169.
28. Wu W.W., Wang G., Baek S.J., Shen R.F. Comparative study of three proteomic quantitative methods, DIGE, cICAT, and iTRAQ, using 2D gel- or LC-MALDI TOF/TOF. J Proteome Res 2006, 5:651-658.
29. Melchior K., Tholey A., Heisel S., Keller A., Lenhof H.P., Meese E., Huber C.G. Proteomic study of human glioblastoma multiforme tissue employing complementary two-dimensional liquid chromatography- and mass spectrometry-based approaches. J Proteome Res 2009, 8:4604-4614.
30. Rajcevic U., Petersen K., Knol J.C., Loos M., Bougnaud S., Klychnikov O., Li K.W., Pham T.V., Wang J., Miletic H., Peng Z., Bjerkvig R., Jimenez C.R., Niclou S.P. iTRAQ-based proteomics profiling reveals increased metabolic activity and cellular cross-talk in angiogenic compared with invasive glioblastoma phenotype. Mol Cell Proteomics 2009, 8:2595-2612.
31. Wang Y., Rudnick P.A., Evans E.L., Li J., Zhuang Z., Devoe D.L., Lee C.S., Balgley B.M. Proteome analysis of microdissected tumor tissue using a capillary isoelectric focusing-based multidimensional separation platform coupled with ESI-tandem MS. Anal Chem 2005, 77:6549-6556.
32. Somasundaram K., Nijaguna M.B., Kumar D.M. Serum proteomics of glioma: methods and applications. Expert Rev Mol Diagn 2009, 9:695-707.
33. Zougman A., Pilch B., Podtelejnikov A., Kiehntopf M., Schnabel C., Kumar C., Mann M. Integrated analysis of the cerebrospinal fluid peptidome and proteome. J Proteome Res 2008, 7:386-399.
34. Tabatabaei P., Bergstrom P., Henriksson R., Bergenheim A.T. Glucose metabolites, glutamate and glycerol in malignant glioma tumours during radiotherapy. J Neurooncol 2008, 90:35-39.
35. Goplen D., Wang J., Enger P.O., Tysnes B.B., Terzis A.J., Laerum O.D., Bjerkvig R. Protein disulfide isomerase expression is related to the invasive properties of malignant glioma. Cancer Res 2006, 66:9895-9902.
36. Wibom C., Pettersson F., Sjostrom M., Henriksson R., Johansson M., Bergenheim A.T. Protein expression in experimental malignant glioma varies over time and is altered by radiotherapy treatment. Br J Cancer 2006, 94:1853-1863.
37. Yip S., Iafrate A.J., Louis D.N. Molecular diagnostic testing in malignant gliomas: a practical update on predictive markers. J Neuropathol Exp Neurol 2008, 67:1-15.
38. Mischak H. Clinical proteomics: a need to define the field and to begin to set adequate standards. Proteomics Clin Appl 2007, 1:148-156.
39. Uhlen M. A Human Protein Atlas for Profiling Cells, Tissues and Organs. In: Chan DW (ed) HUPO2009 World Congress. Humana Press, Toronto, Canada; 2009. p. 265 [HUPO2009 World Congress Proceeding Book; published in sp. edition of Clinical Proteomics, Volume 5, Suppl 1, 2009].
40. Berglund L., Andrade J., Odeberg J., Uhlen M. The epitope space of the human proteome. Protein Sci 2008, 17:606-613.
41. Rockberg J., Lofblom J., Hjelm B., Uhlen M., Stahl S. Epitope mapping of antibodies using bacterial surface display. Nat Methods 2008, 5:1039-1045.
42. Spurrier B., Ramalingam S., Nishizuka S. Reverse-phase protein lysate microarrays for cell signaling analysis. Nat Protoc 2008, 3:1796-1808.
43. Jiang R., Mircean C., Shmulevich I., Cogdell D., Jia Y., Tabus I., Aldape K., Sawaya R., Bruner J.M., Fuller G.N., Zhang W. Pathway alterations during glioma progression revealed by reverse phase protein lysate arrays. Proteomics 2006, 6:2964-2971.
44. Costello CE. Top-down Analysis of Native and Crosslinked Proteins to Locate Modifications and Investigate 3-Dimensional Structures. In: Chan DW (ed) HUPO2009 World Congress. Springer, Toronto; 2009. p.265 [HUPO2009 World Congress Proceeding Book; published in sp. edition of Clinical Proteomics, Volume 5, Suppl 1, 2009].
45. Han X., Aslanian A., Yates J.R. Mass spectrometry for proteomics. Curr Opin Chem Biol 2008, 12:483-490.
46. Lange V., Picotti P., Domon B., Aebersold R. Selected reaction monitoring for quantitative proteomics: a tutorial. Mol Syst Biol 2008, 4:222.
47. Chaurand P., Schwartz S.A., Reyzer M.L., Caprioli R.M. Imaging mass spectrometry: principles and potentials. Toxicol Pathol 2005, 33:92-101.
48. Franck J., Arafah K., Elayed M., Bonnel D., Vergara D., Jacquet A., Vinatier D., Wisztorski M., Day R., Fournier I., Salzet M. MALDI imaging mass spectrometry: state of the art technology in clinical proteomics. Mol Cell Proteomics 2009, 8:2023-2033.
49. Griffin J.L., Kauppinen R.A. A metabolomics perspective of human brain tumours. FEBS J 2007, 274:1132-1139.
50. Spratlin J.L., Serkova N.J., Eckhardt S.G. Clinical applications of metabolomics in oncology: a review. Clin Cancer Res 2009, 15:431-440.
51. Kamleh M.A., Dow J.A., Watson D.G. Applications of mass spectrometry in metabolomic studies of animal model and invertebrate systems. Brief Funct Genomic Proteomic 2009, 8:28-48.
52. Bjerkvig R., Johansson M., Miletic H., Niclou S.P. Cancer stem cells and angiogenesis. Sem Cancer Biol 2009, 19:279-284.
53. Vogel T.W., Zhuang Z., Li J., Okamoto H., Furuta M., Lee Y.S., Zeng W., Oldfield E.H., Vortmeyer A.O., Weil R.J. Proteins and protein pattern differences between glioma cell lines and glioblastoma multiforme. Clin Cancer Res 2005, 11:3624-3632.
54. Billecke C., Malik I., Movsisyan A., Sulghani S., Sharif A., Mikkelsen T., Farrell N.P., Bogler O. Analysis of glioma cell platinum response by metacomparison of two-dimensional chromatographic proteome profiles. Mol Cell Proteomics 2006, 5:35-42.
55. Zhou L., Wang Y., Zhang Y.T., Geng Y.P., Si L.S., Wang Y.L. Proteomics-based analysis of a pair of glioma cell lines with different tumor forming characteristics. Neurosci Lett 2006, 401:59-64.
56. Trog D., Fountoulakis M., Friedlein A., Golubnitschaja O. Is current therapy of malignant gliomas beneficial for patients? Proteomics evidence of shifts in glioma cells expression patterns under clinically relevant treatment conditions. Proteomics 2006, 6:2924-2930.
57. Shim J.H., Kim Y.S., Bahk Y.Y. Proteome profile changes that are differentially regulated by lipid and protein phosphatase activities of tumor suppressor PTEN in PTEN-expressing U-87 MG human glioblastoma cells. Proteomics 2006, 6:81-93.
58. Ngo T.T., Peng T., Liang X.J., Akeju O., Pastorino S., Zhang W., Kotliarov Y., Zenklusen J.C., Fine H.A., Maric D., Wen P.Y., De Girolami U., Black P.M., Wu W.W., Shen R.F., Jeffries N.O., Kang D.W., Park J.K. The 1p-encoded protein stathmin and resistance of malignant gliomas to nitrosoureas. J Natl Cancer Inst 2007, 99:639-652.
59. Puchades M., Nilsson C.L., Emmett M.R., Aldape K.D., Ji Y., Lang F.F., Liu T.J., Conrad C.A. Proteomic investigation of glioblastoma cell lines treated with wild-type p53 and cytotoxic chemotherapy demonstrates an association between galectin-1 and p53 expression. J Proteome Res 2007, 6:869-875.
60. Seyfried N.T., Huysentruyt L.C., Atwood J.A., Xia Q., Seyfried T.N., Orlando R. Up-regulation of NG2 proteoglycan and interferon-induced transmembrane proteins 1 and 3 in mouse astrocytoma: a membrane proteomics approach. Cancer Lett 2008, 263:243-252.
61. Bian X.W., Xu J.P., Ping Y.F., Wang Y., Chen J.H., Xu C.P., Wu Y.Z., Wu J., Zhou X.D., Chen Y.S., Shi J.Q., Wang J.M. Unique proteomic features induced by a potential antiglioma agent, Nordy (dl-nordihydroguaiaretic acid), in glioma cells. Proteomics 2008, 8:484-494.
62. Hill J.J., Moreno M.J., Lam J.C., Haqqani A.S., Kelly J.F. Identification of secreted proteins regulated by cAMP in glioblastoma cells using glycopeptide capture and label-free quantification. Proteomics 2009, 9:535-549.
63. Koncarevic S., Urig S., Steiner K., Rahlfs S., Herold-Mende C., Sueltmann H., Becker K. Differential genomic and proteomic profiling of glioblastoma cells exposed to terpyridineplatinum(II) complexes. Free Radic Biol Med 2009, 46:1096-1108.
64. Liu J., Zheng S., Yu J.K., Zhang J.M., Chen Z. Serum protein fingerprinting coupled with artificial neural network distinguishes glioma from healthy population or brain benign tumor. J Zhejiang Univ Sci 2005, 6:4-10.
65. Khwaja F.W., Nolen J.D., Mendrinos S.E., Lewis M.M., Olson J.J., Pohl J., Van Meir E.G., Ritchie J.C., Brat D.J. Proteomic analysis of cerebrospinal fluid discriminates malignant and nonmalignant disease of the central nervous system and identifies specific protein markers. Proteomics 2006, 6:6277-6287.
66. Khwaja F.W., Duke-Cohan J.S., Brat D.J., Van Meir E.G. Attractin is elevated in the cerebrospinal fluid of patients with malignant astrocytoma and mediates glioma cell migration. Clin Cancer Res 2006, 12:6331-6336.
67. Khwaja F.W., Reed M.S., Olson J.J., Schmotzer B.J., Gillespie G.Y., Guha A., Groves M.D., Kesari S., Pohl J., Van Meir E.G. Proteomic identification of biomarkers in the cerebrospinal fluid (CSF) of astrocytoma patients. J Proteome Res 2007, 6:559-570.
68. Zhang H., Wu G., Tu H., Huang F. Discovery of serum biomarkers in astrocytoma by SELDI-TOF MS and proteinchip technology. J Neurooncol 2007, 84:315-323.
69. Petrik V., Saadoun S., Loosemore A., Hobbs J., Opstad K.S., Sheldon J., Tarelli E., Howe F.A., Bell B.A., Papadopoulos M.C. Serum alpha 2-HS glycoprotein predicts survival in patients with glioblastoma. Clin Chem 2008, 54:713-722.
70. Schuhmann MU, Zucht HD, Nassimi R, Heine G, Schneekloth CG, Stuerenburg HJ, Selle H. Peptide screening of cerebrospinal fluid in patients with glioblastoma multiforme. Eur J Surg Oncol 2010; 36: 201-7.
71. Iwadate Y., Sakaida T., Hiwasa T., Nagai Y., Ishikura H., Takiguchi M., Yamaura A. Molecular classification and survival prediction in human gliomas based on proteome analysis. Cancer Res 2004, 64:2496-2501.
72. Furuta M., Weil R.J., Vortmeyer A.O., Huang S., Lei J., Huang T.N., Lee Y.S., Bhowmick D.A., Lubensky I.A., Oldfield E.H., Zhuang Z. Protein patterns and proteins that identify subtypes of glioblastoma multiforme. Oncogene 2004, 23:6806-6814.
73. Schwartz S.A., Weil R.J., Johnson M.D., Toms S.A., Caprioli R.M. Protein profiling in brain tumors using mass spectrometry: feasibility of a new technique for the analysis of protein expression. Clin Cancer Res 2004, 10:981-987.
74. Chumbalkar V.C., Subhashini C., Dhople V.M., Sundaram C.S., Jagannadham M.V., Kumar K.N., Srinivas P.N., Mythili R., Rao M.K., Kulkarni M.J., Hegde S., Hegde A.S., Samual C., Santosh V., Singh L., Sirdeshmukh R. Differential protein expression in human gliomas and molecular insights. Proteomics 2005, 5:1167-1177.
75. Iwadate Y., Sakaida T., Saegusa T., Hiwasa T., Takiguchi M., Fujimoto S., Yamaura A. Proteome-based identification of molecular markers predicting chemosensitivity to each category of anticancer agents in human gliomas. Int J Oncol 2005, 26:993-998.
76. Odreman F., Vindigni M., Gonzales M.L., Niccolini B., Candiano G., Zanotti B., Skrap M., Pizzolitto S., Stanta G., Vindigni A. Proteomic studies on low- and high-grade human brain astrocytomas. J Proteome Res 2005, 4:698-708.
77. Schwartz S.A., Weil R.J., Thompson R.C., Shyr Y., Moore J.H., Toms S.A., Johnson M.D., Caprioli R.M. Proteomic-based prognosis of brain tumor patients using direct-tissue matrix-assisted laser desorption ionization mass spectrometry. Cancer Res 2005, 65:7674-7681.
78. Mehrian-Shai R., Chen C.D., Shi T., Horvath S., Nelson S.F., Reichardt J.K., Sawyers C.L. Insulin growth factor-binding protein 2 is a candidate biomarker for PTEN status and PI3K/Akt pathway activation in glioblastoma and prostate cancer. Proc Natl Acad Sci USA 2007, 104:5563-5568.
79. Moore L.M., Holmes K.M., Smith S.M., Wu Y., Tchougounova E., Uhrbom L., Sawaya R., Bruner J.M., Fuller G.N., Zhang W. IGFBP2 is a candidate biomarker for Ink4a-Arf status and a therapeutic target for high-grade gliomas. Proc Natl Acad Sci USA 2009, 106:16675-16679.
80. Lin Y., Jiang T., Zhou K., Xu L., Chen B., Li G., Qiu X., Zhang W., Song S.W. Plasma IGFBP-2 levels predict clinical outcomes of patients with high-grade gliomas. Neuro-oncology 2009, 11:468-476.
81. Li J., Zhuang Z., Okamoto H., Vortmeyer A.O., Park D.M., Furuta M., Lee Y.S., Oldfield E.H., Zeng W., Weil R.J. Proteomic profiling distinguishes astrocytomas and identifies differential tumor markers. Neurology 2006, 66:733-736.
82. Khalil A.A. Biomarker discovery: a proteomic approach for brain cancer profiling. Cancer Sci 2007, 98:201-213.
83. Mustafa D.A., Burgers P.C., Dekker L.J., Charif H., Titulaer M.K., Smitt P.A., Luider T.M., Kros J.M. Identification of glioma neovascularization-related proteins by using MALDI-FTMS and nano-LC fractionation to microdissected tumor vessels. Mol Cell Proteomics 2007, 6:1147-1157.
84. Mustafa D., van der Weiden M., Zheng P., Nigg A., Luider TM., Kros J.M. Expression Sites of Colligin 2 in Glioma Blood Vessels. Brain pathology (Zurich, Switzerland) 2008.
85. Li J., Yin C., Okamoto H., Mushlin H., Balgley B.M., Lee C.S., Yuan K., Ikejiri B., Glasker S., Vortmeyer A.O., Oldfield E.H., Weil R.J., Zhuang Z. Identification of a novel proliferation-related protein, WHSC1 4a, in human gliomas. Neuro-oncology 2008, 10:45-51.
86. An J.H., Lee S.Y., Jeon J.Y., Cho K.G., Kim S.U., Lee M.A. Identification of gliotropic factors that induce human stem cell migration to malignant tumor. J Proteome Res 2009, 8:2873-2881.
87. Park C.K., Jung J.H., Park S.H., Jung H.W., Cho B.K. Multifarious proteomic signatures and regional heterogeneity in glioblastomas. J Neurooncol 2009, 94:31-39.